| [1] |
WANG Ting, QIN Yi, XU Xiaowu, YU Xianjun.
New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024
[J]. China Oncology, 2025, 35(1): 1-11.
|
| [2] |
CHEN Hong, CAO Zhiyun.
Recent progress in the construction and application of patient-derived pancreatic cancer organoid models
[J]. China Oncology, 2024, 34(6): 590-597.
|
| [3] |
REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng.
An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
[J]. China Oncology, 2024, 34(12): 1090-1099.
|
| [4] |
WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong.
Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells
[J]. China Oncology, 2024, 34(11): 987-997.
|
| [5] |
TAN Xiaolang, YAO Sha, WANG Guihua, PENG Luogen.
Research on uPAR promoting proliferation, migration, and chemoresistance of pancreatic cancer by inhibiting autophagy via MAPK signaling
[J]. China Oncology, 2024, 34(10): 944-956.
|
| [6] |
LI Tianjiao, YE Longyun, JIN Kaizhou, WU Weiding, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023
[J]. China Oncology, 2024, 34(1): 1-12.
|
| [7] |
CHEN Hong, CHEN Junxia.
Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(4): 342-353.
|
| [8] |
ZENG Cheng, ZHANG Jian.
Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022
[J]. China Oncology, 2023, 33(3): 235-240.
|
| [9] |
FU Qingsheng, JIN Lei, ZHANG Xudong, XU Yingchen, ZHU Chunfu, QIN Xihu, WU Baoqiang.
Effect of tRF-Pro-CGG on the biological behavior of mouse pancreatic cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(3): 241-249.
|
| [10] |
YUE Ming, WANG Liwei, CUI Jiujie.
Research progress on the mechanism of organ-specific lung metastasis in pancreatic cancer
[J]. China Oncology, 2023, 33(11): 1026-1031.
|
| [11] |
JIA Yuming, YE Zeng, DENG Yanli, LI Shengchao, ZHANG Zhilei, WANG Chao, XU Xiaowu, QIN Yi, PENG Li.
The research on FBW7 gene enhances antitumor effect of paclitaxel on pancreatic cancer through GSDME-mediated pyroptosis
[J]. China Oncology, 2023, 33(10): 889-897.
|
| [12] |
WANG Xu, CHENG He, LIU Chen, YU Xianjun.
New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022
[J]. China Oncology, 2023, 33(1): 1-13.
|
| [13] |
ZHUANG Han, LING Chifang, WANG Jiazhou, HAN Xu, JIANG Rui, HU Weigang.
Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study
[J]. China Oncology, 2023, 33(1): 54-60.
|
| [14] |
Diao Xinfeng, Li Xinmao, Hou Liang, Wei Zhixuan.
YTHDF2 promotes progression of glioblastoma via inducing mRNA decay of IGFBP7 and activating PI3K/AKT signaling pathway
[J]. China Oncology, 2022, 32(3): 218-227.
|
| [15] |
LI Yujie, CHEN Hao.
Potential of targeting TROP2 in the treatment of pancreatic cancer
[J]. China Oncology, 2022, 32(3): 268-273.
|